Mass Spectrometry

Using state-of-the-art equipment, researchers of ULg provide innovative solutions in the fields of:

  • Analytical chemistry (volatile and non-volatile small organic compound analysis…)
  • Medical chemistry (toxicology analysis in biological fluids, identification and quantification of new biomarkers, biomarker signature validation…)
  • Biological and pharmaceutical chemistry (biomolecule full characterization, pharmaceutical interaction with protein or DNA target, quantification of metabolites of a new drug…)
  • Biophysics and structural chemistry (structure of supra-molecular assemblies…)

Moreover, our lab investigate and develop new mass spectrometric methodologies such as new ion excitation methods using photons, electrons or hydrogen radicals.


Laser capture microdissection

Picture5Tissue microdissection or laser capture microdissection (LCM) is an automated sample preparation technique enabling the isolation of specific cells from heterogeneous materials under microscopic visualization. LCM is contact-free, thanks to the specimen collection by gravity, which helps to minimize contamination. This precise technique allows the selective analysis of specific regions, down to single cells and the extraction of their proteins and nucleic acids.

LCM allows to obtain answers in a single cell that may otherwise have been missed in a whole tissue scrape that contains a heterogeneous mixture of healthy, stromal and cancer cells. This technique of isolating a pure sample from a heterogeneous mixture allows more efficient and accurate results with downstream microgenomics applications such as next-generation sequencing, Sanger sequencing, PCR and proteomics.

Our specific equipment includes a LDM 7000 LEICA.

Contact [] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.


Our Proteomic GIGA platform is at the forefront of technological innovation and assay development. The facility is hosted by the Mass Spectrometry Laboratory and works in collaboration with the Center for Analytical Research and Technology.

It offers expert services in proteins characterization (sequencing, post-translational modifications, heterogeneity, etc) and targeted quantification (biologics, biomarkers).



Our Genetics GIGA platform is at the forefront of technological innovation and assay development. It offers expert services in high-throughput genomic assays, including array- and NGS-based NSP genotyping, variant detection, transcriptome and epigenome analyses.

In addition, the Genetic Department of the CHU has developed a large expertise in the diagnosis of genetic diseases, including genetic predisposition to cancer, as well as the diagnosis of acquired genetic and epigenetic features in cancers in pediatric and adult patients, and in the analysis of acquired genetic anomalies in diverse malignant tumors (leukemia’s, lymphomas and various solid tumors). The genetic department is one of the 8 Centers for Human Genetics in Belgium and we are BELAC accredited for diagnostic tests for genetic diseases and cancer (ISO 15189).

We are ready to help you in various projects such as patient characterization, metabolic profiling during clinical studies, exploration of SNPs or high throughput DNA sequencing in search for treatment targets and/or markers predictive of response or resistance.

Contact [] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.


Our lab are equipped with state-of-the-art technologies to detect, separate, identify and quantify molecules covering a large chemical space. Non-target and target analyses are performed using Nuclear Magnetic Resonance (NMR) and chromatography coupled to mass spectrometry. Researchers at ULg and CHU have extensive experience working with different matrices such as blood, plasma, milk, urine, saliva, organs/tissues, cell lysates, oils, growth media, plant extracts…

Metabolomics analysis can accurately determine the slightest changes of a molecular profile related to disease onset and progression, therapeutic intervention, genetic modification or environmental variation.